Loading stock data…
Loading stock data…
US$4.39
Get one email when CING crosses your level. Checked every 15 minutes during market hours.
▼ -0.04 (-0.90%)down today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
39.6
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
-0.09
Bearish momentumMACD below its signal line (0.00).
50-day average
4.79
Price belowShort-term trend reference.
200-day average
5.06
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Cingulate Inc. is a clinical-stage biopharmaceutical company that develops pharmaceutical products using a proprietary precision timed-release drug delivery platform. The company concentrates on treatments for attention deficit/hyperactivity disorder and anxiety, aiming to provide medications that deliver more consistent therapeutic coverage over the day while reducing the need for multiple daily doses. Its lead product candidate, CTx-1301 (dexmethylphenidate), is being developed for ADHD, and a…
www.cingulate.com2 strong buy · 7 buy · 1 hold · 0 sell · 0 strong sell (10 analysts, 2026-07-01)
2 strong buy · 7 buy · 1 hold · 0 sell · 0 strong sell (10 analysts, 2026-06-01)
2 strong buy · 6 buy · 1 hold · 0 sell · 0 strong sell (9 analysts, 2026-05-01)
2 strong buy · 6 buy · 1 hold · 0 sell · 0 strong sell (9 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-05-14 | -0.53 | -0.95 | ✗ Miss |
| 2026-03-18 | -1.55 | -0.84 | ✓ Beat |
| 2026-01-28 | 1.03 | 1.03 | ✓ Beat |
| 2025-11-13 | -0.75 | -1.35 | ✗ Miss |
| 2025-08-19 | -0.82 | -1.09 | ✗ Miss |
| 2025-05-08 | -0.98 | -1.04 | ✗ Miss |
Companies in the same industry, via Finnhub